Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps
- PMID: 31309982
- PMCID: PMC9012239
- DOI: 10.1093/infdis/jiz245
Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps
Conflict of interest statement
Comment on
-
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.J Infect Dis. 2020 Jan 14;221(3):346-355. doi: 10.1093/infdis/jiz244. J Infect Dis. 2020. PMID: 31309975 Clinical Trial.
References
-
- Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. https://www.hcvguidelines.org/. Accessed 2 May 2019.
-
- U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0. Accessed 2 May 2019.
-
- Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol 2016; 18:126–34. - PubMed
-
- Uehara THF, Kawaguchi K, Omoto S, et al. Treatment emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2019. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
